Table 2:
Propensity score matched resultsa
| No. of patientsb | HR (95%CI) | Excess risk (95% CI)c | |
|---|---|---|---|
| Female | |||
| Genital infections (composite) | 129,994 | 2.80 (2.63, 2.99) | 87.6 (79.1, 96.7) |
| Canclidal genital infections | 3.35 (3.05, 3.67) | 53.1 (46.4, 60.4) | |
| Male | |||
| Genital infections (composite) | 156,074 | 2.66 (2.30, 3.08) | 11.9 (9.4, 15.0) |
| Canclidal genital infections | 3.35 (2.28, 4.91) | 2.4 (1.3, 4.1) | |
| SGLT2 inhibitors v GLP1 agonists | |||
| Female | |||
| Genital infections (composite) | 142,992 | 2.91 (2.73, 3.10) | 91.0 (82.4, 100.3) |
| Candidal genital infections | 3.60 (3.28, 3.95) | 55.5 (48.7, 62.9) | |
| Male | |||
| Genital infections (composite) | 139,398 | 2.85 (2.42, 3.35) | 12.9 (9.9, 16.4) |
| Candidal genital infections | 3.28 (2.18, 4.94) | 2.5 (1.3, 4.2) | |
| SGLT2 inhibitors v DPP4 inhibitors; Age ≥ 60 | |||
| Female | |||
| Genital infections (composite) | 37,764 | 4.45 (3.83, 5.17) | 90.0 (73.9, 108.7) |
| Candidal genital infections | 5.28 (4.28, 6.52) | 54.6 (41.8, 70.4) | |
| Male | |||
| Genital infections (composite) | 43,078 | 3.30 (2.56, 4.25) | 18.5 (12.6, 26.2) |
| Candidal genital infections | 4.31 (2.16, 8.59) | 3.4 (1.2, 7.8) | |
| Canagliflozin v Dapagliflozin | |||
| Female | |||
| Genital infections (composite) | 49,764 | 0.90 (0.83, 0.97) | −12.0 (−20.3, −1.1) |
| Candidal genital infections | 0.93 (0.84, 1.03) | −4.5 (−10.7, 2.3) | |
| Male | |||
| Genital infections (composite) | 63,352 | 0.99 (0.83, 1.17) | −0.1 (−2.8, 3.0) |
| Candidal genital infections | 1.01 (0.69, 1.46) | 0.0 (−1.0, 1.7) | |
| Canagliflozin v Empagliflozin | |||
| Female | |||
| Genital infections (composite) | 40,336 | 0.97 (0.89, 1.05) | −4.0 (−14.9, 7.9) |
| Candidal genital infections | 0.96 (0.86, 1.07) | −2.9 (−11.1, 6.3) | |
| Male | |||
| Genital infections (composite) | 51,678 | 0.97 (0.80, 1.16) | −0.6 (−4.0, 3.4) |
| Candidal genital infections | 0.70 (0.42, 1.15) | −0.9 (−1.7, 0.5) | |
Abbreviations: GLP1: Glucagon-like peptide-1 agonist; SGLT2: sodium-glucose cotransporter 2 inhibitors; DPP-4: Dipeptidyl peptidase-4 inhibitors
a
Pooled result are reported, see supplement for database specific estimates
b
in both the SGLT2 and comparator group
c
Represents the number of additional cases of genital infections due to SGLT2 inhibitors initiations per 1,000 person years of follow-up